Open AccessAlmitrine: a possible therapeutic strategy for COVID-19?
Author(s) -
Renata Carvalho Cremaschi,
Cristina Frange,
L.R.A. Bittencourt,
Fernando Morgadinho Santos Coelho
Publication year - 2020
Publication title -
revista neurociências
Language(s) - English
Resource type - Journals
eISSN - 1984-4905
pISSN - 0104-3579
DOI - 10.34024/rnc.2020.v28.10941
Subject(s) - respiratory system , coronavirus , chemoreceptor , medicine , respiratory tract , tmprss2 , anosmia , immunology , covid-19 , receptor , disease , infectious disease (medical specialty)
Coronavirus disease 2019 (COVID‐19) remains with no specific treatment, despite the efforts of many scientists around the world. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) penetrates human host banknotes through interaction with angiotensin-converting enzyme 2 and transmembrane protease, serine 2 (TMPRSS2) receptors, located at respiratory tract (upper and lower) and the olfactory epithelium (pathway to the Central Nervous System). The virus causes COVID-19 and sometimes a Severe Acute Respiratory Syndrome (SARS). Several neurological manifestations can be associated with the infection. The SARS-COV-2 neurotropism for cardiorespiratory centers, causing autonomic damage, may contribute to respiratory failure. Almitrine is a respiratory stimulant drug, used in chronic hypoxemic diseases. Almitrine acts in peripheral chemoreceptors and could be a potential treatment for the optimization of chemoreceptors, improving the respiratory control affected by the SARS‐CoV‐2 in patients with COVID-19.